At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
lapatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced or Metastatic Colorectal Cancer
In Brief
A Phase 1 clinical trial evaluating lapatinib, oxaliplatin, and 1 other intervention for Neoplasms, Colorectal. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activity of the combination of drugs in subjects with previously untreated advanced or metastatic colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Colorectal
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedSep 2007
Primary CompletionOct 2008
TodayJul 2026
First PostedSep 28, 2007
Enrollment StartSep 26, 2007
Primary CompletionOct 31, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.8 years ago
Interventions
lapatinibdrug
onced daily Days 1-21
oxaliplatindrug
Day one of each cycle
capecitabinedrug
given BID days 1-14